336 related articles for article (PubMed ID: 27606884)
1. Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.
Madabhavi I; Patel A; Anand A; Panchal H; Parikh S
Clin Respir J; 2018 Feb; 12(2):806-810. PubMed ID: 27606884
[TBL] [Abstract][Full Text] [Related]
2. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
3. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
4. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract][Full Text] [Related]
5. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
6. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
7. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
[TBL] [Abstract][Full Text] [Related]
8. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
9. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
11. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
[TBL] [Abstract][Full Text] [Related]
12. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
[TBL] [Abstract][Full Text] [Related]
13. Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma.
Gennatas S; Stanway SJ; Thomas R; Min T; Shah R; O'Brien ME; Popat S
BMC Cancer; 2013 Apr; 13():207. PubMed ID: 23617826
[TBL] [Abstract][Full Text] [Related]
14. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
15. Widespread renal polycystosis induced by crizotinib.
Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
[TBL] [Abstract][Full Text] [Related]
17. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
19. [ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].
Audigier-Valette C; Girard N; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlesi F
Bull Cancer; 2014 Sep; 101(9):823-31. PubMed ID: 25299566
[TBL] [Abstract][Full Text] [Related]
20. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Camidge DR; Bang YJ; Kwak EL; Iafrate AJ; Varella-Garcia M; Fox SB; Riely GJ; Solomon B; Ou SH; Kim DW; Salgia R; Fidias P; Engelman JA; Gandhi L; Jänne PA; Costa DB; Shapiro GI; Lorusso P; Ruffner K; Stephenson P; Tang Y; Wilner K; Clark JW; Shaw AT
Lancet Oncol; 2012 Oct; 13(10):1011-9. PubMed ID: 22954507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
